Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HFB30132A in Healthy Chinese Adults
NCT05275660Phase 1Completed
- Sponsor
- HiFiBiO Therapeutics
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Enuzovimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by HiFiBiO Therapeutics. Primary endpoints: Number of participants with treatment emergent serious adverse events, Number of participants with treatment emergent adverse events of special interest and 8 more. Started May 2021; status: completed.
02
Drugs
Enuzovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05275660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275660.